Glaukos Reports Strong Preliminary Q4 and Full Year 2025 Net Sales, Reaffirms 2026 Guidance
GKOS sits 33% above its 52-week low of $73.16.
Summary
Glaukos Corporation announced robust preliminary net sales for Q4 and full year 2025, with significant year-over-year growth, and reaffirmed its positive revenue guidance for 2026.
Key Events · Earnings and Guidance · GKOS
-
Strong Q4 2025 Net Sales
Preliminary net sales reached approximately $143 million, marking a 36% increase compared to Q4 2024.
-
Robust Full Year 2025 Performance
Full year preliminary net sales were approximately $507 million, up 32% from 2024.
-
iDose TR Contribution
The iDose TR product contributed significantly, with approximately $45 million in Q4 and $136 million for the full year in US Glaucoma net sales.
-
2026 Guidance Reaffirmed
The company reaffirmed its full year 2026 net sales guidance range of $600 million to $620 million.
Analysis · GKOS · Industrial Applications And Services
The preliminary results indicate strong operational performance, particularly with a 36% increase in Q4 net sales and a 32% increase for the full year 2025. The reaffirmation of 2026 revenue guidance, coupled with a healthy cash position and no debt, provides a positive outlook for the company's continued growth and financial stability. Investors should view these results as a strong indicator of execution across key commercial and development initiatives.
At the time of this filing, GKOS was trading at $96.97 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $73.16 to $163.71. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.